Adicet Bio, Inc. (ACET)Healthcare | Biotechnology | Boston, United States | NasdaqCM
8.55 USD
-0.28
(-3.171%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:58 a.m. EDT
The investment case for Adicet Bio is currently broken by a catastrophic multi-year decline in share price. Over the last seven years, the stock has lost nearly 99% of its value, and the company has endured three consecutive years of negative annual returns. While the balance sheet appears robust on paper with minimal debt relative to cash, the market has clearly priced in a severe deterioration in the underlying business quality, evidenced by the relentless price drop. There is no dividend to provide income, and the recent price action shows no signs of recovery, trading below both its 50-day and 200-day moving averages. The options market reinforces this bearish sentiment, with traders positioning for further downside rather than a rebound. Despite the wide range of analyst price targets, the fundamental reality of a shrinking asset with no earnings growth makes this a dangerous hold for capital preservation. |
| Model | MAE |
|---|---|
| MSTL_74_115 ✓ | 0.100431 |
| MSTL_74 | 0.107860 |
| MSTL_115 | 0.124604 |
| MSTL | 0.135886 |
| AutoETS | 0.155063 |
| AutoTheta | 0.206745 |
| AutoARIMA | 0.232179 |
Forecast horizon: 60 days | Selected: MSTL_74_115
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 3.22 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.502 |
| Excess Kurtosis | -0.14 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.923 |
| Market Cap | 79,927,416 |
| Forward P/E | -2.04 |
| Beta | 1.59 |
| Website | https://www.adicetbio.com |
As of July 11, 2026, 4:58 a.m. EDT: Options activity shows a distinct lack of bullish positioning. Call volume is negligible across all expirations, with open interest concentrated deep in-the-money at strikes far below the current price, suggesting speculative bets on a crash rather than a rally. Conversely, put open interest is heavily skewed toward out-of-the-money strikes (above the current price), indicating significant hedging or bearish speculation that the stock will trade lower. The implied volatility structure supports this view, with elevated IV on the out-of-the-money puts compared to the near-term calls.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.2915597 |
| Address1 | 131 Dartmouth Street |
| Address2 | 3rd Floor |
| All Time High | 2,362.864 |
| All Time Low | 6.01 |
| Ask | 11.12 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 95,910 |
| Average Daily Volume3 Month | 107,072 |
| Average Volume | 107,072 |
| Average Volume10Days | 95,910 |
| Beta | 1.592 |
| Bid | 6.44 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 13.029 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.55 |
| Current Ratio | 7.655 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 9.15 |
| Day Low | 8.55 |
| Debt To Equity | 9.923 |
| Display Name | Adicet Bio |
| Dividend Date | 1,600,214,400 |
| Earnings Timestamp | 1,778,702,400 |
| Earnings Timestamp End | 1,786,651,200 |
| Earnings Timestamp Start | 1,786,651,200 |
| Ebitda | -107,756,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.315 |
| Enterprise Value | -33,909,860 |
| Eps Current Year | -8.86833 |
| Eps Forward | -4.192 |
| Eps Trailing Twelve Months | -13.27 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.1914 |
| Fifty Day Average Change | 0.35860062 |
| Fifty Day Average Change Percent | 0.043777697 |
| Fifty Two Week Change Percent | -29.15597 |
| Fifty Two Week High | 17.44 |
| Fifty Two Week High Change | -8.89 |
| Fifty Two Week High Change Percent | -0.5097477 |
| Fifty Two Week Low | 6.01 |
| Fifty Two Week Low Change | 2.54 |
| Fifty Two Week Low Change Percent | 0.42262894 |
| Fifty Two Week Range | 6.01 - 17.44 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,516,977,000,000 |
| Float Shares | 7,425,831 |
| Forward Eps | -4.192 |
| Forward P E | -2.0395994 |
| Free Cashflow | -50,383,248 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 102 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01079 |
| Held Percent Institutions | 0.63329 |
| Implied Shares Outstanding | 9,348,236 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,767,052,800 |
| Last Split Factor | 1:16 |
| Long Business Summary | Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts. |
| Long Name | Adicet Bio, Inc. |
| Market | us_market |
| Market Cap | 79,927,416 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_310073311 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -108,833,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 80,254,606 |
| Number Of Analyst Opinions | 6 |
| Open | 8.8 |
| Operating Cashflow | -91,339,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 650 503 9095 |
| Previous Close | 8.83 |
| Price Eps Current Year | -0.9641049 |
| Price Hint | 2 |
| Price To Book | 0.6562284 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.542 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.28 |
| Regular Market Change Percent | -3.17101 |
| Regular Market Day High | 9.15 |
| Regular Market Day Low | 8.55 |
| Regular Market Day Range | 8.55 - 9.15 |
| Regular Market Open | 8.8 |
| Regular Market Previous Close | 8.83 |
| Regular Market Price | 8.55 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 116,220 |
| Return On Assets | -0.39442003 |
| Return On Equity | -0.72192 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 9,348,236 |
| Shares Percent Shares Out | 0.0541 |
| Shares Short | 505,580 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 517,922 |
| Short Name | Adicet Bio, Inc. |
| Short Percent Of Float | 0.0543 |
| Short Ratio | 5.87 |
| Source Interval | 15 |
| State | MA |
| Symbol | ACET |
| Target High Price | 100.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 34.83333 |
| Target Median Price | 22.5 |
| Total Cash | 137,592,000 |
| Total Cash Per Share | 13.103 |
| Total Debt | 13,898,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -13.27 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.97514 |
| Two Hundred Day Average Change | -0.42513943 |
| Two Hundred Day Average Change Percent | -0.04736856 |
| Type Disp | Equity |
| Volume | 116,220 |
| Website | https://www.adicetbio.com |
| Zip | 2,116 |